Efficacy of the glyceryl trinitrate transdermal therapeutic system in a dog model of heart failure.
The efficacy of a controlled-release topical dosage form of glyceryl trinitrate (Nitroglycerin Transdermal Therapeutic System, Nitroderm TTS, NTG-TTS; CAS 55-63-0) was studied in the experimental model of congestive heart failure in beagles. NTG-TTS suppressed the increase in left ventricular end-diastolic and central venous pressure, and total peripheral resistance resulting from propranolol, dextran and l-phenylephrine infusion. NTG-TTS antagonized the decrease in cardiac output in this model. These effects of NTG-TTS on congestive heart failure were presumably attributable to the reduction of pre-load, together with direct vasodilation of the peripheral arteries.
Katahira
J
J
Preclinical Research Department, Ciba-Geigy Limited, Takarazuka, Japan.
Tanaka
M
M
Nakao
K
K
Inukai
T
T
D000279:Administration, Cutaneous; D000818:Animals; D002302:Cardiac Output / Q000187:drug effects; D003911:Dextrans / Q000494:pharmacology; D004195:Disease Models, Animal; D004285:Dogs; D005260:Female; D006333:Heart Failure / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects; D008297:Male; D005996:Nitroglycerin / Q000008:administration & dosage / Q000627:therapeutic use*; D010656:Phenylephrine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology
D003911:Dextrans; D010656:Phenylephrine; D011433:Propranolol; D005996:Nitroglycerin